16,287 reports of this reaction
6.1% of all EVOLOCUMAB reports
#4 most reported adverse reaction
ACCIDENTAL EXPOSURE TO PRODUCT is the #4 most commonly reported adverse reaction for EVOLOCUMAB, manufactured by Amgen USA Inc.. There are 16,287 FDA adverse event reports linking EVOLOCUMAB to ACCIDENTAL EXPOSURE TO PRODUCT. This represents approximately 6.1% of all 266,603 adverse event reports for this drug.
Patients taking EVOLOCUMAB who experience accidental exposure to product should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACCIDENTAL EXPOSURE TO PRODUCT is moderately reported among EVOLOCUMAB users, representing a notable but not dominant share of adverse events.
In addition to accidental exposure to product, the following adverse reactions have been reported for EVOLOCUMAB:
The following drugs have also been linked to accidental exposure to product in FDA adverse event reports:
ACCIDENTAL EXPOSURE TO PRODUCT has been reported as an adverse event in 16,287 FDA reports for EVOLOCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACCIDENTAL EXPOSURE TO PRODUCT accounts for approximately 6.1% of all adverse event reports for EVOLOCUMAB, making it a notable side effect.
If you experience accidental exposure to product while taking EVOLOCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.